Grand Mal Seizure Market Research Report- Global Forecast till 2027

Grand Mal Seizure Market information: by drug generation (first, second, third), by drug class (barbiturates, hydantoin, others), by surgery (resective surgery, others), by diagnosis (EEG, MRI, others), and by end users - Global forecast till 2027

ID: MRFR/Pharma/2755-HCR | October 2022 | Region: Global | 80 Pages         

Grand Mal Seizure Market

The Grand Mal Seizure Market is anticipated to reach USD 2.8 billion at CAGR of 4.2% CAGR during the forecast period

Segmentation

By Drug Generation First Generation Second Generation Third Generation
By Drug Class Hydantoin Barbiturates
By Surgery Respective Surgery Others
By Diagnosis Magnetic Resonance Imaging (Mri) Electroencephalogram (Eeg) Blood Tests Computed Tomography (Ct) Others
By End-users Academic And Research Centers Neurological Centers Hospitals Others

Key Players

  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries
  • UCB Celltech
  • Abbott Laboratories
  • Shire Pharmaceuticals Limited
  • Pfizer Inc.
  • Novartis AG

Drivers

  • rising geriatric population who are susceptible to epilepsy
  • rising screening of patients across the world
Speak to Analyst Request a Free Sample

Grand Mal Seizure Market Overview


The Grand Mal Seizure Market is anticipated to reach USD 2.8 billion at CAGR of 4.2% CAGR during the forecast period. Epilepsy is considered to be a neurological disorders group that is recognized by involuntary episodes of vigorous shaking of the complete body or a part of the body. In such a condition, the patient may face disturbance or loss of movements and consciousness along with psychiatric or sensory disturbances. As per the report, in 2015, nearly 24 million people have experienced epilepsy across the world. Grand mal seizures are the most common type of epileptic seizures that can be found worldwide. Grand mal seizures are a type of generalized seizures that affects the entire brain and is also popularly known as tonic-clonic seizures. 


Grand mal seizures usually occur by neurotransmitter imbalances that are influenced by hypertension, fatigue, stress, rapid motion, blood sugar level, lack of sleep, intense lighting, anxiety, and others. Basically, two phases are involved in the grand mal seizures: the clonic and tonic phases. The clonic phase involves relaxation resulting in convulsions and rapid muscle contraction. The tonic phase consists of muscle twitching and loss of consciousness. This phase stays only for a few seconds. Many patients do not respond at all or respond very poorly to the mainline drugs like the ion channel blockers and the Gamma-Aminobutyric Acid Modulators, which have serious adverse effects on the patient like dizziness, depression, fatigue, weight gain, suicidal behavior, and others. 


The Grand Mal Seizure Market Outlook report highlights that the involvement of intended audiences in the present market is contributing significant growth to the market. These intended audiences include academic institutes and universities, global grand mal seizure suppliers and manufacturers, hospitals and clinics, and research and development (R&D) companies. 


COVID-19 Analysis


In the first half of 2020, the covid-19 outbreak has impacted the growth of the Grand Mal Seizure Market. At this time, the social distancing norms, lockdown and shutdown of different places have made everyone sit at home. Moreover, the global market has seen a lack of transportation disruption in the manufacturing chain and supply chain.


However, the adoption of safety measures and new strategies by the market leaders has helped a lot to bring back the Grand Mal Seizure Market to the normal situation. Presently, the worldwide market is expecting to witness significant market revenue in the upcoming years. 


Market Dynamics



  • Key Market Drivers


The Grand Mal Seizure Market is driven due to the rising geriatric population who are susceptible to epilepsy and the rising screening of patients across the world. 


Moreover, the development of better-tolerated third-generation drugs is fuelling the growth of the global market during the forecast period.  



  • Market Challenges


The Grand Mal Seizure Market might experience challenges due to the social stigma relating to epilepsy in various developing countries.


Moreover, the risk associated with the grand mal seizure might be one of the biggest challenges for the global market during the review period. 



  • Market Opportunities


The Grand Mal Seizure Market is expected to bring lucrative opportunities for the market leaders and manufacturers due to the growing screening of patients across the globe. 


The increasing research and developmental initiatives in the field of Grand Mal Seizure are bringing significant opportunities in the Market.



  • Market Restraints


The Grand Mal Seizure Market might get affected due to the lack of innovative drugs and unknown action mechanisms and origin of epilepsy. Also, most anti-epileptic drugs' poor efficiency and efficacy might hamper the global market growth. 


Moreover, the growing patent expiry for anti-epilepsy drugs like Lyrica (scheduled in 2018) and Neurontin (2003) is projected to hinder the Grand Mal Seizure Market Growth during the research period. 


Cumulative Evaluation of The Market


The Grand Mal Seizure Market Trends report shows that the rising technological advancement is propelling the growth of the market and is projected to show significant growth in the upcoming years. 


Moreover, the key leaders are working effectively to enhance the performance of the market for Grand Mal Seizure in the further coming years. 


Market Segmentation


As per the Grand Mal Seizure Market Forecast report, the present market has been divided in terms of drug class, diagnosis, drug generation, surgery, and end-users.



  • By drug class: 


On the basis of drug class segment, the worldwide Market has been segregated into hydantoin, barbiturates, benzodiazepines, phenyltriazine, cyclic GABA analogs, aliphatic carboxylic acid, iminostilbenes, and others. 


Among all, the aliphatic carboxylic acid segment is projected to hold the largest Grand Mal Seizure Market Share by generating 21% of CAGR in 2016. 



  • By diagnosis:


In terms of the diagnosis segment, the Grand Mal Seizure Market has been categorized into magnetic resonance imaging (MRI), electroencephalogram (EEG), blood tests, computed tomography (CT), and others. 



  • By drug generation:


On the basis of the drug generation segment, Market has been classified into the third generation, the second generation, and the first generation.



  • By surgery:


Depending on the surgery segment, the Market has been divided into multiple subpial transections, respective surgery, corpus callosotomy, hemispherectomy, and others. 



  • By end-users:


On the basis of the end-user segment, the Grand Mal Seizure Market has been segregated into academic and research centers, neurological centers, hospitals, and others.


Regional Analysis


Globally, the Grand Mal Seizure Market has been spread across various geographical locations such as North America, the Middle East & Africa, Latin America, Europe, Asia Pacific, and the rest of the world. 


Of these, the Latin American and the North American region is generating a significant market share throughout the forecast timeframe due to the greater expenditure on health care and extensive use of medications in these regions. Moreover, the Grand Mal Seizure Market Size is expanding due to the fastest uptake of drugs and new technology in the US. In addition, the American region is fuelling because of the presence of major medical diagnostic device manufacturers in the region. 


Apart from these, the European market for grand Mal Seizures is considered to be the second-largest market during the forecast period because of the increasing awareness regarding the grand mal seizures and a high disposable income in the region. Moreover, the Asia Pacific region is anticipated to expand rapidly over the research period. In this region, countries like India and China contribute largely and dominate the market for the assessment period. Further, the Middle East & African market for Grand Mal Seizure is driven with the support of the UAE and Saudi Arabia and is further estimated to witness moderate growth in the forecast period. This region is expanding slowly because of the poor healthcare development and poor political and economic conditions. 


Competitive Intensity Within the Industry 


As per the Grand Mal Seizure Market Analysis, significant competition is occurring among the prominent market leaders across the region. These market leaders include:



  • Johnson & Johnson Services, Inc., 

  • GlaxoSmithKline plc,

  • Teva Pharmaceutical Industries

  • UCB Celltech, Abbott Laboratories,

  • Sanofi. Shire Pharmaceuticals Limited,

  • Pfizer, Inc.,

  • Novartis AG.


These market leaders are implying new strategies and ideas like new innovations, partnerships, collaborations, mergers and acquisitions. Moreover, they are also investing largely in research and development relating to Grand Mal Seizure to propel the Grand Mal Seizure Market Value during the review period. 


Recent Market Developments



  • Recently, the market players are focusing on dietary therapy, deep brain stimulation, surgery, vagus nerve stimulation, and responsive neurostimulation that can propel the global market for Grand Mal Seizure in the upcoming years. 


Report Overview


The Grand Mal Seizure Market report is a combination of both primary and secondary research. This report covers the covid-19 analysis, market overview, market dynamics, regional analysis, market segmentation, and competitive analysis. 


Moreover, this report has highlighted the recent developments in the Grand Mal Seizure industry to understand the better performance of the global market. 


Key Industrial Segments


By drug class: 



  • hydantoin, 

  • barbiturates, 

  • benzodiazepines, 

  • phenyltriazine, 

  • cyclic GABA analogs, 

  • aliphatic carboxylic acid, 

  • iminostilbenes, 

  • others


By diagnosis:



  • magnetic resonance imaging (MRI), 

  • electroencephalogram (EEG), 

  • blood tests, 

  • computed tomography (CT), 

  • others


By drug generation:



  • the third generation, 

  • the second generation, 

  • the first generation


By surgery:



  • multiple subpial transactions, 

  • resective surgery, 

  • Corpus callosotomy, 

  • hemispherectomy, 

  • others


By end-users:



  • academic and research center, 

  • neurological centers, 

  • hospitals, 

  • others



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

grand mal seizure market is projected to grow at a 4.2% CAGR between 2017-2023.

The Americas is expected to dominate the grand mal seizure market.

Clonic phase and tonic phase are the two phases of grand mal seizures.

grand mal seizure market is predicted to touch 2.8 billion by 2023.

Major end users of the grand mal seizure market include academic and research center, neurological centers, hospitals, and others.